Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 241.30B +27.8% |
| Revenue (ttm) | 44.94B +9.6% |
| Net Income | 11.09B +17.1% |
| EPS | 5.67 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 22.30 |
| Forward PE | 18.05 |
| Dividend | 3.70 (2.93%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 63,503 |
| Average Volume | 3,501,328 |
| Open | 126.06 |
| Previous Close | 126.46 |
| Day's Range | 126.04 - 126.36 |
| 52-Week Range | 81.10 - 129.54 |
| Beta | 0.46 |
| RSI | 74.97 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.
Novartis to exit listed Indian arm in Rs 1,446cr deal
India Business News: New Delhi: Swiss drug firm Novartis will sell its entire stake of nearly 71% in its listed Indian subsidiary for about Rs 1,446 crore to a clutch of p.
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Novartis (NVS) Sells Majority Stake in Indian Subsidiary for $159 Million
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
Trump says tariffs prompt Novartis to expand U.S. manufacturing
Novartis to sell 70.7% stake in Indian unit for $159M
Novartis India shares surge 14.65% today after Novartis AG to sell 70.68% stake
Friday, February 20: Shares of Novartis India Limited jumped sharply in early trade after its promoter, Novartis AG, agreed to...
Trump meets Novartis CEO, says drugmaker building 11 US plants
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
Novartis Makes $1.8 Billion Bet On Oral Peptides
Novartis Makes $1.8 Billion Bet On Oral Peptides
Novartis (NVS) Partners with Unnatural Products in $1.8B Drug Development Deal
Novartis (NVS) Partners with Unnatural Products in $1.8B Drug Development Deal
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announ...
Novartis' Phase 3 Trial Of Remibrutinib Meets Primary Endpoint In Chronic Inducible Urticaria
(RTTNews) - Novartis AG (NVS,NOVN.SW), a healthcare firm, on Wednesday announced positive results from the Phase 3 trial of its oral drug, Remibrutinib, in chronic inducible urticaria.
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU)1. The primary endpoint ...
A Look Into Novartis Inc's Price Over Earnings
In the current session, the stock is trading at $166.81, after a 1.80% increase. Over the past month, Novartis Inc. (NYSE: NVS) stock increased by 15.64% , and in the past year, by 55.30% . With perf...
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise
On Friday, Novartis AG (NYSE: NVS) shared final results from the Phase 3 ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanraf...
Novartis Reports Positive Data From Phase III ALIGN Study For Vanrafia In IgA Nephropathy
(RTTNews) - Novartis (NVS) announced that final results from a phase 3 trial of Vanrafia support slowing of kidney function decline in patients with IgA nephropathy.
Novartis Says Vanrafia Drug Slows Kidney Function Decline
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy.
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated ...
Novartis (NVS) Gains FDA Orphan Status for New Treatment
Novartis (NVS) Gains FDA Orphan Status for New Treatment
Super Bowl Hot Take: A Barrage of Butts Steals Big Game in Novartis Ad
The Big Game ad puts a spotlight on prostate cancer and relaxing your tight end.